
	January 17, 2008

Now Available:
Dr. Norman Gaylis presents "The Whys and Wherefores of Infusion Therapy"

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

Consumer News: Learn what your patients are reading in the popular press

Too Much of a Good Thing?
Growing use of CT scans is causing concern about radiation exposure...

New from PubMed: Keep up-to-date with what is on PubMed

Incidental Vertebral Fractures on Multidetector CT Images of the Chest: Prevalence and Recognition
Vertebral fractures are under-diagnosed by radiologists using multidetector computed tomography...

Skin: Etanercept Clears Plaque Psoriasis in Children and Adolescents
Etanercept (Enbrel) safely reduces disease severity in children and adolescents with moderate-to-severe plaque psoriasis, and improvements are evident as early as the second week of therapy...

BioPharm Business: Elan, Biogen Idec Gain US FDA Approval of Tysabri for Treatment of Moderate-to-Severe Crohn's Disease
Elan Corp, plc and Biogen Idec announced the approval of a supplemental Biologics License Application for Tysabri (natalizumab) for inducing and maintaining clinical response and remission in adult patients with active moderate-to-severe Crohn's disease...

BioPharm Business: Incyte Reports INCB18424, a Selective JAK2 Inhibitor, Shows Initial Positive Clinical Activity With Rapid Onset of Action in RA and Psoriasis
Incyte Corp announced positive clinical proof-of-concept results with its wholly-owned, internally developed, lead JAK2 (Janus-associated kinase 2) inhibitor, INCB18424, in rheumatoid arthritis (RA) and psoriasis...